AI assistant
Twist Bioscience Corp — Director's Dealing 2018
Nov 6, 2018
31873_dirs_2018-11-06_ad9a0eae-2590-45ac-9420-433a8343db2b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Twist Bioscience Corp (TWST)
CIK: 0001581280
Period of Report: 2018-11-02
Reporting Person: Ever Alpha Fund L.P. (10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-11-02 | Common Stock | C | 3294961 | — | Acquired | 3294961 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-11-02 | Series D Preferred Stock | $ | C | 3294961 | Disposed | Common Stock (3294961) | Direct |
Footnotes
F1: The Series D Preferred Stock has no expiration date and will convert into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering.
F2: Ever Glory Limited is the general partner of Ever Alpha Fund L.P. Ever Glory Limited is a wholly owned subsidiary of Guangfa Xinde Capital Management Limited. Guangfa Xinde Capital Management Limited is a wholly owned subsidiary of Guangfa Investment (Hong Kong) Company Limited. Guangfa Investment (Hong Kong) Company Limited is a wholly owned subsidiary of Guangfa Holding (Hong Kong) Corporation Limited.